Key result
Serum TSP-1 levels were significantly decreased specifically in female patients with major depressive disorder, but did not change pre- and post-ECT or correlate with symptoms.
Why the study?
Thrombospondin-1 was previously reported to increase with electroconvulsive seizure treatment in rats, but whether serum levels are associated with depression and electroconvulsive therapy in humans was unknown.
Are serum levels of TSP-1 associated with major depressive disorder and altered by electroconvulsive therapy?
Case-Control (n=72)
Are serum levels of TSP-1 associated with major depressive disorder and altered by electroconvulsive therapy?
Serum TSP-1 may serve as a female-specific trait marker for major depressive disorder, but it is not responsive to electroconvulsive therapy.
Answers are grounded in this paper and cite their sources.
May mark female MDD as trait biomarker without ECT response; hypothesis-generating for validation in prospective studies.
AIM: Thrombospondin-1 (TSP-1) is an astrocyte-derived synaptogenesis-related factor. It was previously reported to be increased by chronic treatment of electroconvulsive seizure, a model of electroconvulsive therapy (ECT), in rat hippocampus. The aim of this study was to examine whether serum levels of TSP-1 are associated with depression and ECT. METHODS: Serum TSP-1 levels of major depressive disorder (MDD) patients (n = 36) and age- and gender-matched healthy controls (n = 36) were measured by TSP-1 ELISA. MDD patients were diagnosed according to the Diagnostics and Statistical Manual of Mental Disorders-IV-TR and underwent ECT. MDD patients were also analyzed for serum TSP-1 levels pre- and post-ECT. Evaluation of symptoms was obtained using the Hamilton Rating Scale for Depression. RESULTS: Serum TSP-1 levels showed significant decreases specific to female MDD patients. However, TSP-1 did not change pre- and post-ECT, did not correlate with symptoms, nor was not affected by the dose of antidepressants. CONCLUSION: Serum TSP-1 is a possible female-specific factor that reflects depressive trait, but not state.
No takes yet. Share an insight, caveat, or question.
Okada‐Tsuchioka et al. (2019) conducted a case-control in Major depressive disorder (n=72). Major depressive disorder vs. Healthy controls was evaluated on Serum TSP-1 levels. Serum TSP-1 levels were significantly decreased specifically in female patients with major depressive disorder, but did not change pre- and post-ECT or correlate with symptoms.
Synapse has enriched 10 related papers. Consider them for comparative context: